OpGen Inc (OPGN) Stock Is At 52 Week Low Now

July 17, 2017 - By Nellie Frank

The stock of OpGen Inc (NASDAQ:OPGN) hit a new 52-week low and has $0.29 target or 4.00 % below today’s $0.30 share price. The 6 months bearish chart indicates high risk for the $8.00M company. The 1-year low was reported on Jul, 17 by Barchart.com. If the $0.29 price target is reached, the company will be worth $320,000 less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

About 1.34M shares traded or 94.19% up from the average. OpGen Inc (NASDAQ:OPGN) has declined 38.60% since July 17, 2016 and is downtrending. It has underperformed by 55.30% the S&P500.

Analysts expect OpGen Inc (NASDAQ:OPGN) to report $-0.16 EPS on August, 8.They anticipate $0.21 EPS change or 56.76 % from last quarter’s $-0.37 EPS. After having $-0.19 EPS previously, OpGen Inc’s analysts see -15.79 % EPS growth.

More notable recent OpGen Inc (NASDAQ:OPGN) news were published by: Globenewswire.com which released: “OpGen Presents Rapid Acuitas Genetic Test Data at Advances in Genome Biology …” on February 14, 2017, also Bizjournals.com with their article: “Another local life sciences company faces threat of delisting” published on May 16, 2017, Globenewswire.com published: “OpGen Signs Supply Agreement to Use Thermo Fisher Scientific’s Technology to …” on June 19, 2017. More interesting news about OpGen Inc (NASDAQ:OPGN) were released by: Globenewswire.com and their article: “OpGen to Present Advancements in Antibiotic Susceptibility and Whole Genome …” published on May 25, 2017 as well as Globenewswire.com‘s news article titled: “OpGen Highlights Capabilities of its Acuitas® Technologies to Rapidly Predict …” with publication date: April 25, 2017.

OpGen, Inc. is a precision medicine firm using molecular diagnostics and informatics to combat infectious disease. The company has market cap of $8.00 million. The Firm is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. It currently has negative earnings. The Company’s deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.